Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or South Carolina for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to South Carolina only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. South Carolina (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Scott Graupner (NPI 1821438714)

Field	Value
Entity Type	Individual
Organization	Scott Graupner
Address	222 E Medical Ln Ste 400
City	West Columbia
State	SC
ZIP	29169
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	June 25, 2013

Payer Source	Total Paid
Medicare	$2.7M
Medicaid	$0

Key Findings

This provider is a Hematology & Oncology Physician whose billing mix is dominated by high-cost oncology therapeutics and associated imaging/diagnostics. Top medication codes include J9271, J9299, J9022 and J9144 (all monoclonal antibodies / immune checkpoint agents), and the profile also includes radiopharmaceutical and PET/CT utilization such as A9595 and 78815, indicating an operation built around infusion-based cancer therapy and advanced diagnostic imaging services.

Revenue is highly concentrated in a small number of Medicare codes: the precomputed top 3 Medicare codes by revenue account for 48.0% of this provider's total Medicare revenue. Those top three codes are J9271 (23.3%), J9299 (12.9%), and J9022 (11.8%), showing that nearly half of Medicare revenue is driven by a few high-cost oncology agents.

Payer mix is effectively single-payer at the program level: lifetime Medicare revenue is $2.7M and there is no Medicaid billing on file. This concentration means the provider’s reimbursement exposure is tied to Medicare policy and pricing for oncology drugs and imaging with no Medicaid offset reported.

On national competitive standing for the highest-volume oncology drugs, the provider is a modest participant rather than a dominant national outlier. J9271 ranks #652 of 1841 providers (64th percentile, labeled typical), J9299 ranks #266 of 505 providers (47th percentile, labeled typical), and J9022 ranks #17 of 39 providers (58th percentile, labeled typical), which together indicate routine but material participation in widely used checkpoint and targeted therapies.

There are a small number of codes where this provider sits well above peers: J9035 (bevacizumab) is reported as notably above typical national volume at the 98th percentile, and 99215 (high-level E/M visits) also appears at the 98th percentile and is described as notably above typical. By contrast, J9312 (rituximab) is at the 12th percentile (described as typical but relatively low-ranked nationally), suggesting selective emphasis on certain biologic agents over others.

Imaging and radiopharmaceuticals form a meaningful portion of revenue and suggest in‑house or closely coordinated diagnostic services. A9595 accounts for $290.1K (11.0% of Medicare revenue) and ranks #79 of 528 providers (85th percentile), while 78815 contributes $129.4K (4.9% of Medicare revenue) and ranks #1126 of 6566 providers (83rd percentile); this mix signals above‑median use of PET/CT and PET radiotracers relative to national peers.

The provider’s procedural and infusion activity supports an infusion-based oncology practice with bundled chemotherapy administration and supportive medications on site. Examples include 96413 (506 claims), 96416 (104 claims), 96417 (140 claims), and supportive therapeutics such as J2506 (876 claims, pegfilgrastim) and J0897 (8K claims, denosumab), indicating routine chemotherapy administration workflows and utilization of growth-factor and bone-support agents.

The provider has an established NPI history (enumerated 2013-06-25, ~13 years ago) and a mid-sized Medicare footprint by lifetime volume ($2.7M). Tenure plus the concentrated, oncology-focused revenue mix suggests a stable, clinically specialized practice whose commercial positioning will be sensitive to Medicare reimbursement changes for high-cost injectable oncology agents and PET‑based diagnostics.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

86 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	15,400	$40	$616K
J9299	Injection, nivolumab, 1 mg	14,160	$20	$339.8K
J9022	Injection, atezolizumab, 10 mg	4,860	$60	$311K
A9595	Piflufolastat f-18, diagnostic, 1 millicurie	620	$470	$290.1K
J9144	Injection, daratumumab, 10 mg and hyaluronidase‑fihj	6,300	$40	$220.5K
J0897	Injection, denosumab, 1 mg	8,040	$20	$152.8K
78815	PET and CT scans are both standard imaging tools that allow doctors to evaluate the location and metabolic actions of tumors or cancer inside the body before beginning an active treatment regimen.…	180	$720	$129.4K
J9312	Injection, rituximab, 10 mg	1,730	$60	$110.6K
J9035	Injection, bevacizumab, 10 mg	1,580	$60	$90.1K
J2506	Injection, pegfilgrastim, excludes biosimilar, 0.5 mg	880	$80	$65.7K

Showing 1–10 of 86

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 86 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. South Carolina Distribution

Scott Graupner — 5 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — South Carolina

Full comparison — all codes billed, vs. state median

86 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	23	30	19,700	$40	$832K
J9299	10	10	15,760	$20	$432K
J9144	10	10	8,460	$40	$349.4K
J9022	1	10	3,550	$60	$239.1K
J9312	20	20	2,340	$60	$193.7K
A9595	1	10	410	$460	$175.9K
J0897	43	250	2,400	$20	$91.2K
J2506	6	10	740	$80	$55.9K
J1439	16	30	42,750	$1	$42.3K
J9035	4	40	200	$50	$26.1K

Showing 1–10 of 86

Related Providers

Other providers that share a Tax Identification Number (TIN) with Scott Graupner, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Columbus Radiology Corp	OH	Diagnostic Radiology Physician	$0	$49.9M
Lexington Health Inc	SC	General Acute Care Hospital	$0	$27.4M
Lexington County Health Services District Inc	SC	General Acute Care Hospital	$0	$19.2M
Au Medical Associates Emergency Medicine Billing Services, LLC	GA	Emergency Medicine Physician	$0	$8.9M
Lexington Health Inc	SC	Urgent Care Clinic/Center	$0	$8.7M
Antonia Kolokythas	TN	Oral and Maxillofacial Surgery (Dentist)	$0	$5.9M
Lexington Health Inc	SC	Pediatric Adolescent Medicine Physician	$0	$5.7M
Lexington Health Inc	SC	Emergency Medicine Physician	$0	$4.2M
Lexington County Health Serv	SC	General Acute Care Hospital	$0	$4M
Steven Madden	SC	Hematology & Oncology Physician	$4M	$0

Nearby Providers

Other providers in the same ZIP code as Scott Graupner, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Palmetto Infusion Services LLC	SC	Infusion Therapy Clinic/Center	$0	$93.6M
United Cerebral Palsy Of South Carolina, Inc	SC	Intellectual and/or Developmental Disabilities Community Based Residential Treatment Facility	$0	$15.7M
Palmetto Retina Center LLC	SC	Ophthalmology Physician	$0	$10.6M
Karen Park Family Dentistry, P.A.	SC	Dentist	$0	$4.2M
John Payne	SC	Ophthalmology Physician	$4M	$0
John Wells	SC	Ophthalmology Physician	$3.9M	$0
Lexington Treatment Specialists LLC	SC	Methadone Clinic	$76.7K	$3.6M
Lexington Health Inc	SC	Obstetrics & Gynecology Physician	$0	$3.5M
Vijaya Korrapati	SC	Hematology & Oncology Physician	$3.4M	$0
Perrie Ryan	SC	Hematology & Oncology Physician	$3.3M	$0

Scott Graupner — Billing Profile & Reimbursement Data

Sign up for Scott Graupner — Billing Profile & Reimbursement Data policy alerts

Scott Graupner — Billing Profile & Reimbursement Data

Sign up for Scott Graupner — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References